What is Leerink Partnrs’ Estimate for ALDX Q2 Earnings?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Leerink Partnrs issued their Q2 2025 earnings per share estimates for Aldeyra Therapeutics in a research note issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman expects that the biotechnology company will post earnings per share of ($0.23) for the quarter. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.92) per share. Leerink Partnrs also issued estimates for Aldeyra Therapeutics’ Q4 2025 earnings at ($0.33) EPS.

A number of other equities analysts have also recently issued reports on ALDX. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a research note on Friday, April 4th. BTIG Research decreased their price objective on shares of Aldeyra Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a report on Monday, April 7th.

Aldeyra Therapeutics Trading Up 3.8 %

Shares of ALDX opened at $2.20 on Tuesday. Aldeyra Therapeutics has a fifty-two week low of $1.14 and a fifty-two week high of $7.20. The firm’s 50-day simple moving average is $5.39 and its two-hundred day simple moving average is $5.22. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Thursday, March 6th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.30).

Hedge Funds Weigh In On Aldeyra Therapeutics

Several institutional investors have recently bought and sold shares of the business. Hsbc Holdings PLC purchased a new position in shares of Aldeyra Therapeutics in the 4th quarter worth approximately $52,000. Balyasny Asset Management L.P. purchased a new position in shares of Aldeyra Therapeutics during the 4th quarter worth about $56,000. Catalyst Funds Management Pty Ltd raised its position in Aldeyra Therapeutics by 2,083.3% in the 4th quarter. Catalyst Funds Management Pty Ltd now owns 13,100 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 12,500 shares during the period. Regal Investment Advisors LLC bought a new stake in Aldeyra Therapeutics in the fourth quarter worth about $66,000. Finally, Walleye Capital LLC purchased a new position in shares of Aldeyra Therapeutics during the fourth quarter valued at approximately $68,000. Institutional investors own 59.71% of the company’s stock.

Insider Buying and Selling

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the business’s stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total value of $4,828,000.00. Following the sale, the insider now owns 5,875,851 shares in the company, valued at $8,343,708.42. The trade was a 36.65 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 8.50% of the stock is currently owned by insiders.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.